APA (7. basım) Alıntı

Burmester, G. R., Coates, L. C., Cohen, S. B., Tanaka, Y., Vranic, I., Nagy, E., . . . Kinch, C. (2023). Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare.

Chicago Style (17. basım) Atıf

Burmester, Gerd R., et al. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare, 2023.

MLA (9th ed.) Atıf

Burmester, Gerd R., et al. Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Adis, Springer Healthcare, 2023.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..